Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Yes Red, I am glad I have taken your advice year after year and gotten them while they were cheap on the many dips (they still are cheap relatively speaking) when there was “blood in the streets” regarding investor sentiment. Congratulations to our CEO Kim Thompson! I knew his vision and determination would bring us to this point eventually. Great job Ole Boy! I am sure that Kim and the entire growing KBLB team will continue their diligent excellence going forward. Time to assemble the commercialization machine!
Thanks for that sickzone.
I agree and have been steadily buying little by little over the last two weeks. In the latest PR it seems that Kim was setting the table for new investors who may be attracted from what I hope will be the next more exciting PR. We shall see. Go KBLB. JMO
Great find! I like that they are bringing scientist into the mix. We shall see.
“It is said that Quang Nam can completely restore and develop traditional silkworm mulberry growing and silkworm rearing. However, in order to develop sustainably, it is necessary to have a close linkage between farmers, businessmen, scientists and the state and inevitably link up production in the value chain. product. Along with that, in the process of production development, synchronous application of new technical advances in mulberry and silkworm rearing is required.”
I bought my first shares of UQM after watching this Charlie Rose interview of Neil Young many years ago. It’s an interesting interview. The UQM part is about 20 minutes into it. https://charlierose.com/videos/18885
This is from the Motley Fool five days ago:
Sangamo’s stock has been red-hot over the past 12 months due to the growing interest in all-things gene therapy. The backstory is that Sangamo struck a series of licensing deals with biopharma heavyweights Gilead Sciences (NASDAQ: GILD) and Pfizer (NYSE: PFE) to develop next-generation therapies for cancer and rare diseases like the bleeding disorder hemophilia.
The Gilead partnership centers around creating adoptive cell therapies that can be manufactured at scale using Sangamo's zinc-finger nuclease (ZFN) gene-editing platform. The current generation of adoptive cell therapies require extensive manufacturing processes that can delay treatment, and create backlogs of patients.
That being said, Gilead's decision to tap Sangamo's ZFN platform did surprise most Wall Street analysts and industry insiders. The consensus was that Gilead would ultimately go the CRISPR route for its gene-editing needs. After all, Sangamo's ZFN platform is more labor-intensive and time-consuming than CRISPR. With serious questions currently swirling around CRISPR's safety in human subjects, however, Sangamo's ZFN tech was apparently the more compelling choice for Gilead at this stage in the game.
The big ticket item for investors here is that this gene-editing deal with Gilead could eventually translate into a whopping $3 billion in total milestone payments for Sangamo -- that is, if things go according to plan. That's a staggering opportunity for a company with a market cap of less than half that amount at present.
Sangamo's severe hemophilia A partnership with Pfizer is also on track to produce preliminary data by mid-year. If successful, this partnership may trigger buyout talks between the two companies. Pfizer, after all, has deep interests in novel treatments for rare diseases, and the biopharma is currently in the process of ramping up its adoptive cell therapy pipeline as well. Put simply, Sangamo would be a near-perfect fit for Pfizer.
Aside from the possibility of a buyout from one of its partners, Sangamo's deep and robust gene therapy platform also offers up another compelling reason to own this stock right now. Sangamo could run into some bad luck in the clinic, but the sheer breadth of its cutting-edge pipeline should ultimately land the company a commercial-stage product at some point.
So, like its clinical-stage peer Jounce, Sangamo's risk-to-reward ratio is arguably heavily skewed toward the upside as things stand now. The biotech's 10.8% drop last week therefore comes across as an incredible buying opportunity for investors with a long-term mind-set.
From The Motley Fool
Yes, I also have to thank Zincfinger for an early heads up on this one.
Haha. Good one!
https://www.streetinsider.com/dr/news.php?id=13930511&gfv=1
Check of the EXHIBIT INDEX!
Nice day CDXS. Keep them coming!
Commodity?
Trump (Fat Nixon) is unlikely to admit it he was wrong about exiting the trade agreement. Rejoining would be the right thing to do and would be best for American businesses like KBLB, not to mention containing Chinese influence to some degree.
Codexis Appoints Molecular Diagnostics Industry Veteran Shawn Clairmont to Lead High-Performance Enzymes Commercialization
February 15, 2018 | About: CDXS +0%
REDWOOD CITY, Calif., Feb. 15, 2018 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading protein engineering company, announces the appointment of Shawn Clairmont to the newly created position of Senior Director, Molecular Diagnostics. Codexis is expanding into the molecular diagnostics industry by developing and commercializing high-performance enzymes for use in next generation sequencing (NGS) and polymerase chain reaction (PCR/qPCR) applications. Clairmont will be responsible for all commercial activities related to the molecular diagnostics enzyme product line, including product launches and market and pricing strategies. She reports to Michael Aldridge, Codexis’ Senior VP Corporate & Strategic Development.
“We welcome Shawn to Codexis as we prepare to commercially launch our first high-performance enzymes for the molecular diagnostics industry,” said Aldridge. “Shawn brings us significant global experience in product launches and commercial account management as well as established relationships with key molecular diagnostic firms and industry opinion leaders. We look forward to calling upon her expertise in developing successful strategies as we bring new enzymes into this established market.”
Warning! GuruFocus has detected 6 Warning Signs with CDXS. Click here to check it out.
CDXS 30-Year Financial Data
The intrinsic value of CDXS
Peter Lynch Chart of CDXS
“This is an exciting time in molecular diagnostics as new technologies, such as liquid biopsy, create the need for high-performance enzymes,” said Clairmont. “Codexis is uniquely positioned to use its CodeEvolver® protein engineering platform to develop enzymes aimed at improving the sensitivity and precision of these tests in identifying biomarkers of interest. I’m delighted to join the Codexis team.”
Clairmont has 13 years of molecular diagnostics industry experience. Most recently she served as Chief Operating Officer of BRIDGenomics, a molecular diagnostics and medical device marketing consultancy providing business development and strategic marketing expertise. She previously served for eight years at the molecular diagnostics company QIAGEN in a variety of positions with increasing responsibility, most recently as Director of Sales, America, on the Global Advanced Molecular Pathology Team. Prior to QIAGEN, Clairmont was a technical marketing representative and account manager at bioArray Solutions LTD. She holds an MBA from the College of Saint Scholastica in Duluth, Minn. and a BA in biology from Saint Olaf College in Northfield, Minn.
About Codexis, Inc.
Codexis, Inc. is a leading protein engineering company that applies its technology to the development of biocatalysts for commercial manufacture of pharmaceuticals and fine chemicals, as well as the development of enzymes as biotherapeutics and for molecular diagnostics. Codexis’ proven technology enables implementation of biocatalytic solutions to meet customer needs for rapid, cost-effective and sustainable manufacturing. For more information, see www.codexis.com.
I just got a response from Jon regarding an email I sent to him on the website. This does not appear to be a big deal and will be fixed soon.
————-
Thank you ***,
I'm on the phone with our web hosting provider now to see what the problem is on their end.
————-
Well said.
“Apple of real estate?”
RDFN is being overtaken by another real estate brokerage company who will be more like the Amazon of real estate. That Completely cloud-based low overhead revenue generating blockbuster is EXPI. Agents and brokers are flocking to it in droves, jumping ship from very established brokerages like REMAX And all the other brick and mortar old school businesses.
I know. Enjoy the esoterica and load up while it last.
Promises promises. Go KBLB!!!
I truly doubt anyone here who actually owns shares would agree with this absurd notion.
Right on Daddio!
Well stated rayo. Especially your questions regarding DS. I’m wondering if DS may become our new mass-market line as we look forward to future announcements of silks that are even more specific to future military needs.
This should be a great KBLB shareholder year !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
I enthusiastically believe that based on where we are starting the year.!!!!
I enjoyed the little gearshift the author of that article made at the end.
You do know there is a copy of your outgoing emails in your “sent box”, right? Happy holidays.
Yes bananarama, a mountainous load of horse dust in that one.
Are you considering adding more shares Danny?
Thanks for that GT!
“ Empty barrels make the most noise.” - Malcolm. J. Fraser, Jr. Ph.D.
He said this many years ago referring to something else but it seems apropos for our competitors today.
You are the man! Good job!
A. to you for Excellent action JEvans1!
A. Excellent
If the market substantially disagrees with me over the next several weeks I will definitely consider it an opportunity to add shares and buy into any dips.
Not a KBLB competitor, “Instead, the researchers drew on recently-developed biochemistry techniques that use micropatterned surfaces in order to concentrate proteins and form organic nanowires, coatings or sheets.”
Interesting possible medical applications though.
At this point this company is beginning to excite many visionary realtors who are changing the old brick and mortar expensive ways of doing business for them to what is the obvious future of real estate. Most average people in this industry have not even heard of this company yet. But people in retail had never heard of Amazon.com early in it’s development either. The investment community will soon get wind of what is happening here and at that point institutional investors as well as mom and pop investors will want a piece of the future of real estate.
“Get’um while they are cheap “
Yepper!!!
Very well explained.
first mike you are a treasure to this message board.
I did the way you write man!
Always have.